Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 89Precursor Cell Lymphoblastic Leukemia-Lymphoma 80Leukemia 75Myelodysplastic Syndromes 72Leukemia, Lymphocytic, Chronic, B-Cell 67Lymphoma, Non-Hodgkin 66Multiple Myeloma 58Hodgkin Disease 54Lymphoma, Mantle-Cell 53Lymphoma, Large B-Cell, Diffuse 50Lymphoma, Follicular 49Leukemia, Myeloid, Chronic-Phase 48Lymphoma 44Lymphoma, B-Cell, Marginal Zone 43Burkitt Lymphoma 43Myeloproliferative Disorders 41Lymphoma, Large-Cell, Immunoblastic 39Leukemia, Myelomonocytic, Chronic 38Leukemia, Myeloid, Accelerated Phase 38Congenital Abnormalities 37Anemia, Refractory, with Excess of Blasts 33Leukemia, Myelogenous, Chronic, BCR-ABL Positive 30Dendritic Cell Sarcoma, Interdigitating 30Blast Crisis 30Recurrence 29Graft vs Host Disease 29Primary Myelofibrosis 25Waldenstrom Macroglobulinemia 23Myelodysplastic-Myeloproliferative Diseases 22Lymphoma, T-Cell, Cutaneous 22

Interventions

Docetaxel 171Radiotherapy 144Magnetic Resonance Spectroscopy 142Leuprolide 112Prednisone 108enzalutamide 102Radiosurgery 101Abiraterone Acetate 94Androgen Antagonists 91Goserelin 83bicalutamide 81gallium 68 PSMA-11 70Surveys and Questionnaires 63apalutamide 57Specimen Handling 56acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55Radiation 47Gonadotropin-Releasing Hormone 45Standard of Care 44Biopsy 44Brachytherapy 42Radiotherapy, Intensity-Modulated 40Blood Specimen Collection 40darolutamide 39abiraterone 39cabazitaxel 35Exercise 35Carboplatin 33Pluvicto 32Triptorelin Pamoate 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Prostatic Neoplasms × Cyclosporine × Clear all
NCT00922129 2014-01-14

Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

St. Joseph's Healthcare Hamilton

Phase 2/3 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡